Organon & Co. (NYSE: OGN) stock closed at 20.47 per share at the end of the most recent trading day (a 1.94% change compared to the prior day closing price) with a volume of 1.66M shares and market capitalization of 5.09B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 9950 people. Organon & Co. CEO is Kevin Ali.

The one-year performance of Organon & Co. stock is -45.57%, while year-to-date (YTD) performance is -26.71%. OGN stock has a five-year performance of %. Its 52-week range is between 18.87 and 38.09, which gives OGN stock a 52-week price range ratio of 5.62%

Organon & Co. currently has a PE ratio of 7.40, a price-to-book (PB) ratio of 1.84, a price-to-sale (PS) ratio of 1.60, a price to cashflow ratio of 11.70, a PEG ratio of 2.32, a ROA of 9.29%, a ROC of 13.88% and a ROE of -75.34%. The company’s profit margin is 17.25%, its EBITDA margin is 29.70%, and its revenue ttm is $4.69 Billion , which makes it $18.43 revenue per share.

Of the last four earnings reports from Organon & Co., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.18 for the next earnings report. Organon & Co.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Organon & Co. is Moderate Buy (2.5), with a target price of $32.29, which is +61.65% compared to the current price. The earnings rating for Organon & Co. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Organon & Co. has a dividend yield of 3.79% with a dividend per share of $1.12 and a payout ratio of -%.

Organon & Co. has a Neutral technical analysis rating based on Technical Indicators (ADX : 71.31, ATR14 : 0.61, CCI20 : 3.18, Chaikin Money Flow : 0.17, MACD : -0.68, Money Flow Index : 56.31, ROC : 0.20, RSI : 44.89, STOCH (14,3) : 71.86, STOCH RSI : 1.00, UO : 62.64, Williams %R : -28.14), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Organon & Co. in the last 12-months were: Aaron Falcione (Option Excercise at a value of $0), Ali Kevin (Option Excercise at a value of $0), Fiedler Susanne (Option Excercise at a value of $0), Geralyn S. Ritter (Option Excercise at a value of $0), Joseph T. Morrissey (Option Excercise at a value of $0), Joseph T.. Morrissey (Option Excercise at a value of $0), Kathryn Dimarco (Sold 0 shares of value $0 ), Kevin Ali (Option Excercise at a value of $0), Kirke Weaver (Option Excercise at a value of $0), Matthew M. Walsh (Option Excercise at a value of $0), Rachel A. Stahler (Option Excercise at a value of $0), Sandra Milligan (Option Excercise at a value of $0), Susanne Fiedler (Option Excercise at a value of $0), Vittorio Nisita (Option Excercise at a value of $0)